PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript

Key event: PAVmed held a special meeting/webcast on March 27, 2026 called to order by CEO Lishan Aklog with senior management, outside counsel and the transfer agent in attendance. Management's remarks were procedural—outlining webcast voting (which revokes prior proxies), Q&A submission, and access to the stockholder list. The excerpt contains no financial metrics, guidance, transactions, or material corporate announcements that would affect valuation.

Analysis

The special-meeting context is a classic binary governance catalyst: votes that authorize financing, equity grants, or board changes can compress or expand float by tens of percent within days and reprice valuation multiples accordingly. For a small-cap medtech like PAVM, even a modest financing authorization (10–30% of current market cap) can drive immediate downside as forward EPS/dilution expectations reset, while rejection of management proposals can induce management lock-up risk and operational drift.

Registry and transfer-agent mechanics matter more than usual here. Low institutional ownership and a retail-heavy cap table lengthen settlement and voting timelines, increasing the chance of post-announcement volatility and borrow squeezes for shorts; monitor borrow fees — a transient >20–30% fee would materially raise short costs and force tactical unwind decisions. The presence of outside counsel and formal proxy infrastructure raises the prior probability of contested votes or legal follow-ons, which typically extend the event horizon from days into months with option skew steepening.

Tail risks run both ways: rapid dilutive financing or a negotiated sale to a strategic buyer could swing equity ±30–60% over a 0–90 day window; litigation or regulatory pushback could prolong downside for 6–12 months and compress liquidity further. The most likely near-term reversals are either activist entry (which can stabilize price by forcing clearer terms) or a failed vote that leaves management with constrained capital, both realizable within 2–6 weeks.

Operationally, treat positions as event-driven with concentrated sizing and active borrow/option management. Execution should prioritize flexible instruments (liquid puts/calls or secured short positions with predefined stop-outs) and a paired-hedge to remove sector beta, because the primary risk is idiosyncratic governance rather than fundamentals in the next 30–90 days.

Key Decisions for Investors

• Short PAVM equity pre-vote (initiate size 1–2% NAV, target -25–35% within 0–30d). Use a strict stop at +12% and monitor borrow fee—if borrow >20%/annum, replace with put purchases instead to cap carrying cost.
• Buy PAVM Jun-2026 puts (3-month tenor) roughly 15–30% OTM as an asymmetric hedge against dilutive authorization or contested vote outcomes; allocate <0.5% NAV per lot, target 3x+ payoff if the stock gaps down post-vote, max loss = premium.
• Event pair: short PAVM / long XLV (or IHI) to strip sector beta. Size the pair so sector exposure nets to zero; this isolates idiosyncratic governance risk and aims for relative alpha capture over 0–90 days with stop-loss on net delta movement of 8–10%.
• Post-vote tactical long (if vote rejects dilutive measures or management announces buyback/strategic alternative): buy within 1–3 trading days after clarity, target +40–60% upside over 1–6 months, hard stop -20%. Keep allocation conditional on clear, non-dilutive outcomes.